Relenza is a drug owned by Glaxosmithkline. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 15, 2014. Details of Relenza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6294572 | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(11 years ago) |
Expired
|
| US5648379 | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(12 years ago) |
Expired
|
| US5360817 | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(13 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Relenza is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Relenza's family patents as well as insights into
ongoing legal events
on those patents.
Relenza's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Relenza:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection | GlaxoSmithKline | NA | COMPLETED
(Jul 1, 2026) | PHASE2 |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) | George Washington University | NA | RECRUITING
(Jul 1, 2026) | PHASE2 |
Generic Launch
Generic Release Date:
Relenza's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 15, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Relenza Generics:
There are no approved generic versions for Relenza as of now.
About Relenza
Relenza is a drug owned by Glaxosmithkline. It is used for preventing influenza. Relenza uses Zanamivir as an active ingredient. Relenza was launched by Glaxosmithkline in 1999.
Approval Date:
Relenza was approved by FDA for market use on 26 July, 1999.
Active Ingredient:
Relenza uses Zanamivir as the active ingredient. Check out other Drugs and Companies using Zanamivir ingredient
Treatment:
Relenza is used for preventing influenza.
Dosage:
Relenza is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG | POWDER | Prescription | INHALATION |